David Durrant
Frederick National Laboratory for Cancer Research(US)National Cancer Institute(MY)National Cancer Institute(US)Center for Cancer Research(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Protein Kinase Regulation and GTPase Signaling, Cell death mechanisms and regulation, Cardiac Ischemia and Reperfusion, Phosphodiesterase function and regulation
Most-Cited Works
- → PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer(2014)206 cited
- → Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction(2010)161 cited
- → Mammalian Target of Rapamycin (mTOR) Inhibition with Rapamycin Improves Cardiac Function in Type 2 Diabetic Mice(2013)150 cited
- Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response.(2003)
- → Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding(2022)134 cited
- → Targeting the Raf kinases in human cancer: the Raf dimer dilemma(2017)129 cited
- → Rapamycin protects against myocardial ischemia–reperfusion injury through JAK2–STAT3 signaling pathway